Home FEATURED LumiraDx SARS-CoV-2 Ag Surveillance Test Launches in the U.S.

LumiraDx SARS-CoV-2 Ag Surveillance Test Launches in the U.S.

0

LumiraDx, a next-generation point of care diagnostics testing company, announced the US launch of its COVID-19 Surveillance Test, for environments such as schools and workplaces.

Lumiradx Announces Us Launch Of Its Rapid Onsite Covid-19 Surveillance Test

The LumiraDx SARS-CoV-2 Ag Surveillance Test allows simultaneous testing of up to five samples on a small, portable instrument with cost per sample as low as $4. With digital results in less than 12 minutes from sample application and a comprehensive connectivity solution, it is designed to measure population health metrics in real-time to help prevent the spread of infection using an affordable, easy-to-use, onsite testing platform. LumiraDx’s announcement comes at a time when schools across the U.S. are assessing how to both bring students back to in-person learning while also monitoring for outbreaks to ensure they can stay safe and open.

Pooja Pathak, LumiraDx Chief Product Officer explained, “Our rapid onsite COVID-19 Surveillance Test offers options that can fit into a variety of different use-cases to support a safe return to school or the workplace and instill confidence in groups about their environment. By pooling up to five samples at one time, the LumiraDx SARS-CoV-2 Ag Surveillance test provides an efficient, accurate and cost-effective way to implement a surveillance testing program.”

Details of LumiraDx’s COVID-19 diagnostic and surveillance testing options are also available through Open and Safe Schools, in partnership with The Rockefeller Foundation’s National Testing Action Program (NTAP), to support state public health and school leaders to leverage federal government programs and resources and implement school COVID-19 testing programs to safely reopen and stay open.

Exit mobile version